FAQ

Parietaria

Known as: Parietarias, Pellitories, Pellitory 
A plant genus of the family URTICACEAE which is the most common cause of pollinosis in Mediterranean countries. It is the source of 'allergen Par o I… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1956-2017
0102019562016

Related topics

Related topics

3 relations
Microbiologicalaspects of radiation effectsphysiological aspects

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Parietaria
physiological aspects
Microbiological
aspects of radiation effects

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Double-blind, placebo-controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance.
Allergy to Parietaria causes significant morbidity in most Mediterranean areas. The aim of this study is to investigate the… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2004
2004
Biological characterization of glutaraldehyde-modified Parietaria judaica pollen extracts.
BACKGROUND Allergoids are widely used in specific immunotherapy (SIT) for the treatment of IgE-mediated allergic diseases, but… (More)
Is this relevant?
2003
2003
Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate.
BACKGROUND Immunotherapy is a recognized treatment for allergic respiratory diseases. OBJECTIVE To study the usefulness of… (More)
Is this relevant?
2003
2003
Identification of cross-reactive and genuine Parietaria judaica pollen allergens.
BACKGROUND The weed Parietaria judaica is one of the most important pollen allergen sources in the Mediterranean area… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study.
BACKGROUND Specific immunotherapy (SIT) is a recognized way of treating IgE-mediated respiratory diseases. The clinical outcome… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology.
Allergic rhinitis (AR) is a high-prevalence disease in many developed countries, affecting about 10±20% of the general population… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1999
1999
Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis.
BACKGROUND Sublingual-swallow immunotherapy was recently recognized in the World Health Organization Position Paper (Allergen… (More)
Is this relevant?
1999
1999
Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial.
BACKGROUND The local (noninjection) routes of immunotherapy are presently regarded as viable therapeutic options for respiratory… (More)
Is this relevant?
1996
1996
Rush sublingual immunotherapy in Parietaria allergic patients.
Forty patients, monosensitized to Parietaria judaica with a clinical history of at least two years of rhinoconjunctivitis with or… (More)
Is this relevant?
1995
1995
Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study.
A double-blind, placebo-controlled study of immunotherapy was conducted in 31 patients with allergic rhinitis due to Parietaria… (More)
Is this relevant?